PMID- 28693234
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 14
IP  - 1
DP  - 2017 Jul
TI  - Relapsed anaplastic lymphoma kinase-positive large B-cell lymphoma expressed 
      cluster of differentiation 4 and cytokeratin: An initially misdiagnosed case 
      corrected by immunoglobulin kappa locus gene rearrangement detection.
PG  - 787-791
LID - 10.3892/ol.2017.6180 [doi]
AB  - Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a rare 
      lymphoma subtype. The present study investigated a refractory nodal ALK-positive 
      LBCL case in a 28-year-old Chinese male. It was initially misdiagnosed as 
      ALK-positive anaplastic large cell lymphoma; however, the patient's lesions 
      relapsed and spread widely following a short remission for chemotherapy and the 
      patient succumbed to the disease 3 months' post-autologous stem cell 
      transplantation; thus, a revision was performed. Histologically, the tumor cells 
      exhibited a characteristic immunoblastic morphology with marked cellular 
      pleomorphism. All lesions shared the same immunoprofiles, including granular 
      cytoplasmic ALK staining patterns and a lack of cell lineage-associated markers, 
      with the exception of cluster of differentiation (CD)45 and CD4. CD30 expression 
      was revealed to be negative and CD138 staining was observed to be positive, 
      additionally, cytokeratin was expressed aberrantly in a relapsed tumor biopsy. 
      Fluorescence in situ hybridization studies demonstrated breakage and extra copies 
      of the ALK gene in >/=30% of cells. Final clarification was provided by the 
      detection of immunoglobulin kappa locus (IGK) gene rearrangement in clonality studies 
      [but notimmunoglobulin heavy locus (IGH) and immunoglobulin lambda locus (IGL) genes]. 
      This aggressive entity requires distinct modalities of standard treatment, and 
      may be ignored owing to its rarity in routine pathology laboratories. BIOMED-2 
      polymerase chain reaction assays, including for IGH, IGK and IGL genes, are 
      essential for the detection of gene rearrangement.
FAU - Shi, Yunfei
AU  - Shi Y
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Li, Xianghong
AU  - Li X
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Song, Yuqin
AU  - Song Y
AD  - Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Zhou, Lixin
AU  - Zhou L
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Feng, Qin
AU  - Feng Q
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Zhang, Chen
AU  - Zhang C
AD  - Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Liu, Weiping
AU  - Liu W
AD  - Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Bai, Yanhua
AU  - Bai Y
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
FAU - Lai, Yumei
AU  - Lai Y
AD  - Department of Pathology, Key Laboratory of Carcinogenesis and Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital and 
      Institute, Beijing 100142, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170517
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5494706
OTO - NOTNLM
OT  - B-cell lymphoma
OT  - anaplastic lymphoma kinase
OT  - clonality
OT  - cluster of differentiation 4
OT  - cytokeratin
EDAT- 2017/07/12 06:00
MHDA- 2017/07/12 06:01
PMCR- 2017/05/17
CRDT- 2017/07/12 06:00
PHST- 2015/08/08 00:00 [received]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/07/12 06:01 [medline]
PHST- 2017/05/17 00:00 [pmc-release]
AID - OL-0-0-6180 [pii]
AID - 10.3892/ol.2017.6180 [doi]
PST - ppublish
SO  - Oncol Lett. 2017 Jul;14(1):787-791. doi: 10.3892/ol.2017.6180. Epub 2017 May 17.